Eczema, Atopic
16
5
5
8
Key Insights
Highlights
Success Rate
80% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
12.5%
2 terminated out of 16 trials
80.0%
-6.6% vs benchmark
25%
4 trials in Phase 3/4
25%
2 of 8 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 8 completed trials
Clinical Trials (16)
A Study to Learn About Study Medicine Called PF-08049820 in People With Eczema
Dupilumab Step-down Strategy to Maintain Remission in Adult and Adolescents Patients With Atopic Dermatitis
Evaluation of 611 in Combination With Topical Corticosteroid in Participants With Moderate to Severe Atopic Dermatitis
A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
Study to Evaluate Soquelitinib in Participants With Moderate to Severe AD
A Study of the Effects of Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis
Phase 2 Randomized Double-blind Study to Assess Topical Zabalafin Hydrogel Vs Vehicle in Mild to Moderate AD.
A Study to Learn About the Study Medicine Etrasimod in Adults With Moderate to Severe Atopic Dermatitis (AD) Who Have Already Tried Treatments Taken by Mouth or by Injection
Anti-relapse Efficacy and Tolerance Assessment of a Cosmetic Cream for Very Dry, Irritated to Atopic Sensitive Skin.
The Effectiveness of a Topical Palmitoylethanolamide (PEA) Formulation (Levagen+) for Reducing Symptoms of Eczema
Nutrients-fortified Egg Consumption on Eczema Condition in Individuals With Eczema
Safety and Efficacy of Quadriderme® in the Treatment of Impetiginous Eczema (Study P05134AM4)
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis
A Study in Subjects With Moderate Atopic Dermatitis
Study of Dupilumab Auto-injector Device When Used by Patients With Atopic Dermatitis
Long-term Safety of Protopic in Atopic Eczema